RxDoctor Payments Data

Kayla Lovett, NP

Family · Macon, GANPI 1902327679

Payments from drug & device makers

$2,852in general payments, 2019–2025

Across 79 payments — averaging $36.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Johnson & Johnson$436
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$231
  • Boston Scientific$164
  • Abbott$145
  • E.r. Squibb & Sons, L.L.C.$68
  • plus $361 from 11 others

What the payments were for

  • Travel & lodging$1,10639%
  • Food & beverage$1,74661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,852 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$175,445
Medicare patients
790
Services billed
2,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban570$526,607
EntrestoSacubitril/Valsartan180$181,236
XareltoRivaroxaban171$156,738
FarxigaDapagliflozin Propanediol200$129,899
MultaqDronedarone Hcl18$18,634
Flecainide Acetate276$13,091
Metoprolol Succinate686$9,029
Mexiletine Hcl106$8,184
Amiodarone Hcl372$7,056
BrilintaTicagrelor13$5,890
Quinidine Gluconate11$5,858
Midodrine Hcl65$5,557
Dofetilide45$3,935
Propafenone Hcl88$3,868
Pyridostigmine Bromide99$3,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$526,607570 claims
NovartisEntresto$44$181,236180 claims
Johnson & JohnsonXarelto$436$156,738171 claims
AstraZenecaFarxiga, Brilinta$61$135,789213 claims
Sanofi-aventis U.S. LLCMultaq$44$18,63418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →